Featured products: Ultimaster™ Sirolimus Eluting Coronary Stent System, Ultimaster™ Tansei™ Sirolimus Eluting Coronary Stent System, Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System
Assessment of ‘safety’ refers to
the side-effect profile and clinical events experienced (eg stroke, myocardial infarction,
unplanned revascularisation). BMS, bare-metal stent; DAPT, dual antiplatelet
therapy; MACCE, major adverse cardiac and cerebral events; MACE, major adverse
coronary events; MCB, major or clinically relevant non-major bleeding; NACE,
net adverse clinical endpoints; OFDI, optical frequency domain imaging; PCI,
percutaneous coronary intervention; STEMI, ST-segment elevation myocardial
infarction; TLF, target lesion failure.
MASTER DAPT is the largest multi-center randomized controlled study to confirm the safety and efficacy of abbreviated DAP in HBR patients following stenting procedures with Ultimaster Family DES. Learn more.
This is HCP only content
website and cannot be refused. Other cookies are only placed if you choose to do so. For further information, please read our cookies policy.
Essential cookies to ensure the website functions well.
Cookies to help us measure the general use of our website.
Cookies that save personal information while browsing.